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Abstract
Background Endovascular treatment (ET) in orally anticoagulated (OAC) patients has not been evaluated in randomized 
clinical trials and data regarding this issue are sparse.
Methods We analyzed data from the German Stroke Registry-Endovascular Treatment (GSR-ET; NCT03356392, date of 
registration: 22 Nov 2017). The primary outcomes were successful reperfusion defined as modified thrombolysis in cerebral 
infarction (mTICI 2b-3), good outcome at 3 months (modified Rankin scale [mRS] 0–2 or back to baseline), and intracranial 
hemorrhage (ICH) on follow-up imaging at 24 h analyzed by unadjusted univariate and adjusted binary logistic regression 
analysis. Additionally, we analyzed mortality at 3 months with adjusted binary logistic regression analysis.
Results Out of 6173 patients, there were 1306 (21.2%) OAC patients, 479 (7.8%) with vitamin K antagonists (VKA) and 
827 (13.4%) with non-vitamin K antagonist oral anticoagulation (NOAC). The control group consisted of 4867 (78.8%) 
non-OAC patients. ET efficacy with the rates of mTICI 2b-3 was similar among the three groups (85.6%, 85.3% vs 84.3%, 
p = 0.93 and 1). On day 90, good outcome was less frequent in OAC patients (27.8%, 27.9% vs 39.5%, p < 0.005 and < 0.005). 
OAC status was not associated with ICH at 24 h (NOAC: odd’s ratio [OR] 0.89, 95% confidence interval [CI] 0.67–1.20; 
VKA: OR 1.04, CI 0.75–1.46).
Binary logistic regression analysis revealed no influence of OAC status on good outcome at 3 months (NOAC: OR 1.25, CI 
0.99–1.59; VKA: OR 1.18, CI 0.89–1.56) and mortality at 3 months (NOAC: OR 1.03, CI 0.81–1.30; VKA: OR 1.04, CI 
0.78–1.1.37).
Conclusions ET can be performed safely and successfully in LVO stroke patients treated with OAC.
Clinical trial registration‑URL http://www.clini caltr ials.gov. Unique identifier: NCT03356392.
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Introduction
Stroke treatment for large vessel occlusion (LVO) strokes 
has been revolutionized in 2015 by the publication of the so-
called HERMES trials (Highly Effective Reperfusion Evalu-
ated in Multiple Endovascular Stroke Trials) [3, 4, 6, 8, 18]. 
Since then, endovascular treatment (ET) is the standard of 
care in LVO ischemic strokes apart from intravenous throm-
bolysis (IVT). Nevertheless, it remains unclear whether ET 
is safe and efficacious in certain patient subgroups. In par-
ticular, ET in OAC stroke patients has not been evaluated 
formally in the HERMES trials. OAC—variably defined—
was even an exclusion criterion in some of them. [3, 4, 8, 
18] Since then, several mostly small retrospective and four 
prospective observational studies investigated ET in anti-
coagulated patients [2, 5, 9–17, 19, 21, 22]. Because of the 
overwhelming success of ET, large randomized-controlled 
trials on this topic are not to be expected in the future due to 
ethical concerns. Therefore, we evaluated the safety and effi-
cacy of ET for LVO stroke in a large cohort of OAC patients 
compared to non-OAC patients within the prospectively 




The study cohort consisted of patients included to the GSR-
ET, an academic, prospective, multicenter registry study for 
the systematic evaluation of the outcome, safety, and process 
parameters of ET in standard of care in Germany. It has been 
described in depth recently [1, 20]. In brief, all consecutive 
adult patients with LVO stroke with an intention to be treated 
with ET at 25 German study centers were included to the 
GSR-ET. For this current evaluation, all GSR-ET patients 
were analyzed who were either orally anticoagulated or not 
anticoagulated at the time of stroke based on the local neu-
rologist’s evaluation of the patient’s medication history and 
laboratory results if performed locally. Laboratory investi-
gations such as INR or anti factor Xa activity, etc. were not 
systematically performed and documented in the registry to 
confirm the medication history. Patients without information 
on anticoagulation therapy were excluded from the analysis.
Data collection
Source data were collected at 25 stroke centers in Germany 
between June 2015 and December 2019, and were assessed 
and rated by the local neurointerventionalists and neurologists. 
Codified data were stored in a web-based electronic database 
hosted at the University Medical Center Hamburg-Eppendorf.
Efficacy and safety outcomes
The primary efficacy outcomes were the successful reca-
nalization defined as modified thrombolysis in cerebral 
infarction (mTICI) score 2b-3 analyzed by the local neuro-
interventionalist and the modified Rankin scale (mRS) after 
3 months analyzed by the local neurologist either during 
an outpatient visit or by phone call if the patient could not 
come to the outpatient clinic. Good outcome at 3 months 
was defined according to mRS 0–2 or back to baseline to 
account for possible pre-stroke disability. The primary 
safety outcomes were presence of intracranial hemorrhage 
(ICH) on routine follow-up imaging at 24 h according to 
the ECASS II (European Cooperative Acute Stroke Study 
[part II]) definition [7], irrespective of the presence of new 
clinical symptoms and without registry documentation of 
the specific ICH subtype. A secondary analysis included the 
prediction of good outcome on the mRS at 3 months, death 
at 3 months and ICH on follow-up imaging at 24 h by the 
anticoagulation status adjusted for age, sex, comorbidities, 
concomitant antiplatelet therapy, stroke severity, and con-
comitant IVT therapy.
Statistical analysis
Data are presented as mean ± standard deviation (SD) or 
counts and percentages as applicable. Data were analyzed 
by Kruskal–Wallis test, chi-squared test, or Fisher’s exact 
test as applicable. A Bonferroni correction for multiple 
testing was used. Differences were accepted as statistically 
significant for the following p values: p < 0.05, p < 0.01 and 
p < 0.005. For secondary analysis, a binary logistic regres-
sion analysis adjusting for potential confounder variables 
was performed with 95% confidence intervals (CI). Poten-
tial confounder variables were determined from meaningful 
baseline between-group differences of univariate analysis 
and chosen based on clinical experience (IVT, smoking, 
atrial fibrillation, diabetes mellitus, arterial hypertension, 
antiplatelet therapy, sex, age, NIHSS on admission, and 
pmRS). Additionally, for mRS at d90, an ordinal regression 
shift analysis was performed. All tests were performed with 
IBM®  SPSS® Statistics Version 26.
Results
Baseline patient characteristics
In total, 6636 patients were analyzed of whom 6173 patients 
fulfilled the inclusion criteria. 1306 (21.2%) patients were 
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treated with OAC: 479 (7.8%) patients had OAC with vita-
min K antagonists (VKA) and 827 (13.4%) patients with 
non-vitamin K antagonist oral anticoagulants (NOAC). The 
control group consisted of 4867 (78.8%) non-OAC patients. 
OAC patients were older (VKA 77.7 ± 10.9 years, NOAC 
77.7 ± 10.9 years vs no OAC 72.0 ± 13.5 years, p < 0.005) 
and more NOAC patients were female (52.6% and 57.8% 
vs 49.5%, p = 0.11 and < 0.005). Concomitant antiplatelet 
therapy was less frequent among OAC patients (5.6% and 
9.4% vs 37.4%, p < 0.005). As expected, OAC patients had 
more often atrial fibrillation (86.9% and 87.5% vs 29.9%, 
p < 0.005) but also arterial hypertension (88.4% and 86.4% 
vs 75.3%, p < 0.005). Also, among OAC patients, diabetes 
mellitus (25.2% and 28.4% vs 20.7%, p = 0.05 and < 0.005) 
and hyperlipidemia (48.4% and 45.5% vs 37.9%, p < 0.005) 
were more frequent, while smoking was less prevalent 
(17.5% and 19.4% vs 27.3%, p < 0.005). Premorbid func-
tional status analyzed by the premorbid mRS was worse in 
the OAC patients (median 0 and 0 vs 0, interquartile range 
2 and 2 vs 1, p < 0.005) (see Table 1).
Stroke, imaging, and treatment characteristics
Clinical stroke severity analyzed by the National Institute of 
Health Stroke Scale (NIHSS) showed more severe strokes in 
OAC patients (15 and 15 vs 14, p = 0.05 and < 0.005). The 
Alberta Stroke Program Early CT Score (ASPECTS) was 
equally distributed among the three groups (9 and 9 vs 9, 
p = 0.79 and 1). Occlusion site of the LVO was similar in all 
three groups except for extracranial Carotid artery occlusion 
which was less frequent among NOAC patients (2.6% vs 
6.9% in non-OAC patients, p < 0.005). Also, multiple LVO 
and occlusion sides were similarly distributed among orally 
anticoagulated patients and the control group. As expected, 
IVT was less frequently performed in OAC patients (26.7% 
and 11.0% vs 59.4%, p < 0.005). Whether IVT in these OAC 
patients was performed because of subtherapeutic anticoagu-
lation or because these patients were misclassified as non-
OAC patients at the time of IVT initiation remains specula-
tive as the GSR-ET did not collect data on this question. If 
performed on site, IVT was started less fast in OAC than in 
non-OAC patients (door-to-needle time in minutes 38 ± 33 
and 46 ± 26 vs 33 ± 49, p < 0.005), while in drip-and-ship 
patients, door-to-needle time was not different (− 93 ± 118 
and − 72 ± 60 vs − 87 ± 75, p = 0.28 and 0.72). ET was initi-
ated (door-to-groin puncture time in minutes 89 ± 133 and 
97 ± 156 vs 101 ± 151, p = 0.21 and 0.13) and terminated 
(door-to-flow restoration time in minutes 137 ± 148 and 
137 ± 149 vs 139 ± 134, p = 1 and 0.19) similarly fast in OAC 
compared to non-OAC patients. With regards to stroke etiol-
ogy, cardioembolic stroke was more frequent among OAC 
patients both VKA and NOAC patients (88.9% and 83.8% 
vs 40.7%, p < 0.005). Large artery atherosclerosis (4.4% and 
4.7% vs 30.1%, p < 0.005) and undetermined cause (3.3% 
and 6.2% vs 23.3%, p < 0.005) were less frequent among 
OAC patients. Also, other determined causes were less fre-
quent among VKA patients (3.3% vs 5.9%, p = 0.04), while 
they were similarly frequent among NOAC patients (5.3% 
vs 5.9%, p = 1) (see Table 2).
Efficacy and safety of ET
Successful reperfusion (mTICI 2b-3) after ET was 
achieved with equal frequency among orally anticoagu-
lated patients (85.6% and 85.3% vs 84.3%, p = 0.93 and 
1) (see Table 3). While on day 90, good outcome was less 
frequent in OAC patients in univariate analysis (31.3%, 
31.1% vs 41.4%, p < 0.005) (see Table 3) binary logistic 
regression analysis with adjustment for pmRS, NIHSS, 
age, sex, antiplatelet medication, arterial hypertension, 
Table 1  Baseline patient characteristics
OAC oral anticoagulation, VKA vitamin K antagonist, NOAC non-vitamin K antagonist oral anticoagulant, pmRS premorbid modified Rankin 
scale
Parameter No OAC VKA p value NOAC p value Included patients, n (%)
n (%) 4867 (78.8) 479 (7.8) n. a 827 (13.4) n. a 6173 (100)
Age, mean ± SD 72.0 ± 13.5 77.7 ± 10.9  < 0.005 77.7 ± 10.9  < 0.005 6169 (99.9)
Female, n (%) 2409 (49.5) 252 (52.6) 0.11 469 (57.8)  < 0.005 6170 (100)
Antiplatelet therapy, n (%) 1819 (37.4) 27 (5.6)  < 0.005 78 (9.4)  < 0.005 6173 (100)
Arterial hypertension, n (%) 3632 (75.3) 419 (88.4)  < 0.005 703 (86.4)  < 0.005 6112 (99.0)
Diabetes mellitus, n (%) 998 (20.7) 119 (25.2) 0.05 231 (28.4)  < 0.005 6107 (98.9)
Hyperlipidemia, n (%) 1823 (37.9) 228 (48.4)  < 0.005 368 (45.5)  < 0.005 6093 (98.7)
Atrial fibrillation, n (%) 1438 (29.9) 413 (86.9)  < 0.005 715 (87.5)  < 0.005 6107 (98.9)
History of smoking, n (%) 1208 (27.3) 72 (17.5)  < 0.005 144 (19.4)  < 0.005 5568 (90.2)
pmRS, median (min, max; inter-
quartile range)
0 (0, 5; 1) 0 (0, 5; 2)  < 0.005 0 (0, 5; 2)  < 0.005 6005 (97.3)
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diabetes mellitus, atrial fibrillation, smoking, and IVT 
performed revealed no statistically significant influence of 
oral anticoagulation status on good outcome at 3 months 
(NOAC: odd’s ratio [OR] 1.25, confidence interval [CI] 
0.99–1.586; VKA: OR 1.18, CI 0.89–1.56) (see Fig. 1 
and electronic supplemental Table 1). This finding was 
confirmed with an ordinal regression shift analysis of the 
mRS at d90 which did not reveal a statistically significant 
Table 2  Clinical stroke, imaging, and treatment characteristics
OAC oral anticoagulation, VKA vitamin K antagonist, NOAC non-vitamin K antagonist oral anticoagulant, NIHSS National Institute of Health 
Stroke Scale, ASPECTS Alberta Stroke Program Early CT Score, ACA anterior cerebral artery, PCA posterior cerebral artery, BA basilar artery, 
VA vertebral artery, IVT intravenous thrombolysis, SD standard deviation
Parameter No OAC VKA p value NOAC p value Included patients, n (%)
NIHSS, median (min, max) 14 (0, 42) 15 (0, 42) 0.05 15 (0, 42)  < 0.005 6078 (98.5)
ASPECTS, median (min, max) 9 (1, 10) 9 (1, 10) 0.79 9 (1, 10) 1 4830 (78.2)
Occlusion site, n (%)
 Carotid artery extracranial 333 (6.9) 22 (4.6) 0.11 21 (2.6)  < 0.005 6094 (98.7)
 Carotid artery intracranial without Carotid-T 261 (5.4) 26 (5.5) 1 30 (3.7) 0.08
 Carotid artery intracranial including Carotid-T 746 (15.5) 91 (19.1) 0.08 135 (16.5) 1
 M1 proximal 1629 (33.9) 142 (29.8) 0.15 280 (34.3) 1
 M1 distal 977 (20.3) 93 (19.5) 1 161 (19.7) 1
 M2 982 (20.5) 100 (21.0) 1 172 (21.1) 1
 ACA 104 (2.2) 18 (3.8) 0.07 22 (2.7) 0.74
 PCA 122 (2.5) 14 (2.9) 1 26 (3.2) 0.69
 BA 485 (10.1) 35 (7.4) 0.13 71 (8.7) 0.46
 VA 96 (2.0) 8 (1.0) 0.10 5 (1.1) 0.32
Occlusion side
 Right, n (%) 2114 (43.4) 200 (41.8) 1 355(42.9) 1 6173 (100)
 Left, n (%) 2333 (47.9) 255 (53.2) 0.06 418 (50.5) 0.35
 n. a., e.g., BA, n (%) 492 (10.1) 34 (7.1) 0.07 72 (8.7) 0.46
 Multiple, n (%) 101 (2.1) 10 (2.1) 1 21 (2.5) 0.87
 IVT yes, n (%) 2892 (59.4) 128 (26.7)  < 0.005 91 (11.0)  < 0.005 6173 (100)
 IVT yes and on site, n (%) 1674 (34.4) 55 (6.7)  < 0.005 72 (15.0)  < 0.005 6173 (100)
 Door-to-needle time IVT on site, minutes, mean ± SD 33 ± 49 38 ± 33  < 0.005 46 ± 26  < 0.005 1686 (93.6)
 Door-to-needle time IVT drip-and-ship, minutes, 
mean ± SD
− 87 ± 75 − 93 ± 118 0.28 − 72 ± 60 0.72 1310 (88.6)
 Door-to-groin puncture time, mean ± SD 101 ± 151 89 ± 133 0.21 97 ± 156 0.13 5827 (94.4)
 Door-to-flow restoration time, mean ± SD 139 ± 134 137 ± 148 1 137 ± 149 0.19 5091 (82.4)
Stroke etiology, n (%)
 Cardioembolic 1982 (40.7) 426 (88.9)  < 0.005 693 (83.8)  < 0.005 6173 (100)
 Large artery atherosclerosis 1466 (30.1) 21 (4.4)  < 0.005 39 (4.7)  < 0.005
 Other determined cause 285 (5.9) 16 (3.3) 0.04 44 (5.3) 1
 Undetermined cause 1134 (23.3) 16 (3.3)  < 0.005 51 (6.2)  < 0.005
Table 3  Safety and efficacy outcomes in univariate analysis
OAC oral anticoagulation, VKA vitamin K antagonist, NOAC non-vitamin K antagonist oral anticoagulation anticoagulant, mTICI modified 
thrombolysis in cerebral infarction, ICH intracranial hemorrhage, mRS modified Rankin scale
Parameter No OAC VKA p value NOAC p value Included patients, n (%)
Reperfusion rate (mTICI 2b–3), n (%) 4032 (84.3) 404 (85.6) 0.93 701 (85.3) 1 6077 (98.4)
ICH 24 h, n (%) 712 (14.6) 60 (12.5) 0.44 97 (11.7) 0.06 6173 (100)
mRS 0–2 on d90, n (%) 1672 (39.5) 116 (27.8)  < 0.005 197 (27.9)  < 0.005 5353 (86.7)
Good outcome (mRS 0–2 or back to 
baseline) on d90, n (%)
1744 (41.4) 130 (31.3)  < 0.005 218 (31.1)  < 0.005 5332 (86.4%)
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influence of OAC status on the mRS shift (NOAC: OR 
0.90, CI 0.75–1.09; VKA: OR 0.93, CI 0.75–1.15) (see 
electronic supplemental Table 2). The same was true for 
mortality at 3 months (NOAC: OR 1.03, CI 0.81–1.30; 
VKA: OR 1.04, CI 0.78–1.37) (see Fig. 2 and electronic 
supplemental Table  3). With regards to safety, in the 
majority of the patients, ICH at 24 h was determined on 
CT scans (n = 5079, 82%), while MRI only was used in a 
minority of 618 patients (10%). A small subgroup of 229 
patients (3.7%) was investigated with CT and MRI scans. 
Neither univariate analysis nor binary logistic regression 
analysis revealed a statistically significant influence of the 
oral anticoagulation status on ICH on follow-up imaging at 
24 h (univariate: p = 0.44 and 0.06; binary logistic regres-
sion: NOAC: OR 0.90, CI 0.67–1.20; VKA: OR 1.04, CI 
0.75–1.46) (see Table 3, Fig. 3 and electronic supplemen-
tal table 4). Interestingly, within the VKA and the NOAC 
group IVT did not increase the risk for ICH at 24 h in 
univariate analysis (VKA: ICH at 24 h and IVT vs no IVT: 
12.5% vs 12.5%, p = 1.0; NOAC: ICH at 24 h and IVT vs 
no IVT: 11.0% vs 11.8%, p = 1.0).
Fig. 1  Binary logistic regres-
sion analysis for good outcome 
(mRS 0–2 or back to base-
line) at d90. mRS modified 
Rankin scale, IVT intravenous 
thrombolysis, NIHSS National 
Institute of Health Stroke Scale, 
pmRS premorbid modified 
Rankin scale, VKA vitamin K 
antagonist, NOAC non-vitamin 
K oral anticoagulation antico-
agulant
Fig. 2  Binary logistic regres-
sion analysis for mortality at 
d90. IVT intravenous thrombol-
ysis, NIHSS National Institute 
of Health Stroke Scale, pmRS 
premorbid modified Rankin 
scale, VKA vitamin K antago-
nist, NOAC non-vitamin K oral 
anticoagulant
Fig. 3  Binary logistic regres-
sion analysis for ICH at 24 h. 
ICH intracranial hemorrhage, 
IVT intravenous thrombolysis, 
NIHSS National Institute of 
Health Stroke Scale, pmRS 
premorbid modified Rankin 
scale, VKA vitamin K antago-
nist, NOAC non-vitamin K oral 
anticoagulant
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Discussion
The key findings of our retrospective analysis of a large 
German prospectively collected observational cohort of 
LVO stroke patients who received ET in view of their OAC 
status are as follows: ET in LVO OAC patients is effective 
and safe with regards to reperfusion rate and postinterven-
tional ICH. Moreover, OAC status did not have a negative 
influence on the long-term functional outcome after ET. 
Although LVO OAC patients performed worse on the mRS 
at 3 months, their OAC status did not affect the rate of 
good functional outcome and mortality at 3 months after 
adjustment for possible confounding variables. The poorer 
performance of OAC patients on the mRS at 3 months 
might at least be in part explained by their worse pre-
morbid functional status (higher premorbid mRS), their 
older age, and the more sever strokes in NOAC patients 
(higher NIHSS). All three of these variables had a nega-
tive impact on the rate of good outcome at 3 months in 
the multivariate analysis. In addition, comorbidities were 
more frequent among OAC patients. In contrast, differ-
ences in the pre-interventional imaging on admission as a 
possible confounder for the clinical efficacy of ET in OAC 
patients can be excluded as ASPECTS on admission and 
type and side of LVO were in general comparable among 
OAC and non-OAC LVO stroke patients. Also, ET was 
initiated and finished equally fast in OAC and non-OAC 
patients. This excludes a prolongation of the procedural 
times in non-OAC patients due to higher rates of IVT or 
in OAC patients due to a more difficult decision process 
before performing ET and/or IVT which could have had an 
impact on the technical and clinical outcomes.
Our analysis comprises the highest number of patients 
with 6173 in total and 1306 OAC patients compared to 
the recently published studies with a total number of 
patients ranging from 28 to 1913 and a number of OAC 
patients ranging from 26 to 320 [2, 5, 9–17, 19, 21, 22]. 
Most studies published retrospectively collected data, but 
four studies were prospective cohort studies [2, 5, 9–17, 
19, 21, 22]. With regards to technical efficacy of ET, if 
reported, all studies showed similar reperfusion rates in 
OAC and non-OAC patients as in our GSR-ET cohort [2, 
5, 9, 11, 16, 19, 21, 22]. Nevertheless, the reperfusion 
rates were distributed heterogeneously among the differ-
ent studies ranging from 64 to 93% [2, 5, 9, 11, 16, 19, 21, 
22]. Additionally, one study compared ET in VKA and 
NOAC patients and reported on better reperfusion rates 
among NOAC patients [12] which was not reflected by 
our data showing similar reperfusion rates among OAC 
and non-OAC patients. Clinical efficacy of ET in OAC 
patients compared to non-OAC patients analyzed by the 
mRS at 3 months was reported to be good in most of the 
recently published studies [2, 9, 11, 16, 17, 21, 22]. Nev-
ertheless, one Czech study found that an mRS 0–2 on day 
90 seemed to be less frequent among patients on antico-
agulation therapy, but those patients were older and had 
more comorbidities [5]. Similarly, another study reported 
worse outcome on d90 among patients on VKA, but again 
this turned out to be mainly attributable to higher age [19]. 
Supporting these observations, in our own analysis after 
adjustment for possible confounding factors including age 
and comorbidities, neither NOAC nor VKA treatment did 
have a negative impact on the long-term clinical efficacy of 
ET. With regards to mortality, one French study reported 
a higher mortality rate at three months in anticoagulated 
patients anticoagulated with VKA, NOAC, or heparin 
[11]. Another recent multicenter observational cohort 
study published together with a study-level meta-analysis 
found an increased mortality at 90 days specifically for 
VKA patients but not for NOAC patients receiving MT 
[13]. In general, other published studies [2, 5, 9, 16, 21, 
22] and our own data did not support this observation: in 
our patients, neither VKA nor NOAC intake on admission 
increased mortality on d90 after MT. These findings on the 
mortality rate are in accordance with the published ICH 
rates as a safety parameter that did not seem to be higher 
among the OAC patients as in our cohort although reported 
differentially detailed [2, 5, 9–11, 14, 16, 17, 19, 21, 22]. 
Interestingly, the multicenter observational cohort study 
that had already reported on increased mortality among 
VKA patients also found increased rates of symptomatic 
intracranial hemorrhage among these patients which might 
at least explain the higher mortality rates [13]. Our own 
study did not see higher ICH rates among VKA and NOAC 
patients, although our data are not directly comparable as 
we evaluated any ICH on 24 h imaging that means not only 
symptomatic but also asymptomatic.
In summary, our analysis of the GSR-ET as the largest 
available cohort supports the general impression from the 
literature that ET is safe and efficacious in OAC patients. 
In particular, long-term functional outcome and mortality 
were not influenced by OAC status. Additionally, intracra-
nial hemorrhage rates were not increased.
Nevertheless, our analysis has several limitations: first, our 
data are of observational character. Therefore, generalizabil-
ity has to be assumed with caution only. Yet, given the over-
whelming success of ET in LVO strokes, it will be difficult to 
generate randomized-controlled data on this topic in the future 
due to ethical concerns which underscores the importance of 
large retrospective analyses such as ours. Second, the OAC sta-
tus of our patients was not verified by laboratory results such 
as INR, specific drug activity measurement, etc. as they were 
not broadly documented in our study database. This might 
have led to misclassification of some patients. Third, data on 
some parameters were missing which might have influenced 
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our interpretation of the results. Fourth, ICH on postinterven-
tional imaging was not further characterized in the registry 
which limits the interpretation of the safety of ET in OAC 
patients. Additionally, in a majority of the patients, hemor-
rhagic transformation at 24 h was determined by CT scans 
without further distinguishing between dual-energy and ordi-
nary CT scan within the registry. CT scans at 24 h might not be 
able to differentiate fairly enough between ICH and postinter-
ventional blood–brain barrier disruption (BBRD) compared to 
imaging at 72 h or alternative imaging modalities such as MRI.
Conclusion
ET in OAC patients with acute LVO ischemic strokes should 
be strongly considered as it is a safe and efficacious treatment.
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